Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
04
04
2023
accepted:
12
12
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
11
1
2024
Statut:
epublish
Résumé
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac
Identifiants
pubmed: 38212337
doi: 10.1038/s41467-023-44389-3
pii: 10.1038/s41467-023-44389-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2024. The Author(s).
Références
Calin, R. et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS 30, 761 (2016).
pubmed: 26730568
doi: 10.1097/QAD.0000000000000987
Li, J. Z. et al. Time to viral rebound after interruption of modern antiretroviral therapies. Clin. Infect. Dis. 74, 865–870 (2022).
pubmed: 34117753
doi: 10.1093/cid/ciab541
Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343 (2016).
pubmed: 26588174
Assoumou, L. et al. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 29, 2003 (2015).
pubmed: 26355572
doi: 10.1097/QAD.0000000000000734
Fidler, S. et al. Virological blips and predictors of post treatment viral control after stopping ART started in primary HIV infection. J. Acquir. Immune. Defic. Syndr. 74, 126 (2017).
pubmed: 27846036
doi: 10.1097/QAI.0000000000001220
Frange, P. et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49–e54 (2016).
pubmed: 26762993
doi: 10.1016/S2352-3018(15)00232-5
Goujard, C. et al. Hiv-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir. Ther. 17, 1001–1009 (2012).
pubmed: 22865544
doi: 10.3851/IMP2273
Hocqueloux, L. et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24, 1598 (2010).
pubmed: 20549847
doi: 10.1097/QAD.0b013e32833b61ba
Lisziewicz, J. et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340, 1683–1683 (1999).
pubmed: 10348681
doi: 10.1056/NEJM199905273402114
Lodi, S. et al. Immunovirologic Control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch. Intern. Med. 172, 1252–1255 (2012).
pubmed: 22826124
doi: 10.1001/archinternmed.2012.2719
Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified From 14 clinical studies. J. Infect. Dis. 218, 1954–1963 (2018).
pubmed: 30085241
pmcid: 6217727
doi: 10.1093/infdis/jiy479
Perkins, M. J. et al. Brief report: prevalence of posttreatment controller phenotype is rare in HIV-infected persons after stopping antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 75, 364 (2017).
pubmed: 28394856
pmcid: 5473334
doi: 10.1097/QAI.0000000000001393
Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211 (2013).
pubmed: 23516360
pmcid: 3597518
doi: 10.1371/journal.ppat.1003211
Stöhr, W. et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 8, e78287 (2013).
pubmed: 24205183
pmcid: 3808338
doi: 10.1371/journal.pone.0078287
Van Gulck, E. et al. Immune and viral correlates of “secondary viral control” after treatment interruption in chronically HIV-1 infected patients. PLoS ONE 7, e37792 (2012).
pubmed: 22666392
pmcid: 3364270
doi: 10.1371/journal.pone.0037792
Etemad, B. et al. HIV post-treatment controllers have distinct immunological and virological features. Proc. Natl Acad. Sci. USA 120, e2218960120 (2023).
pubmed: 36877848
pmcid: 10089217
doi: 10.1073/pnas.2218960120
Hurst, J. et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat. Commun. 6, 8495 (2015).
pubmed: 26449164
doi: 10.1038/ncomms9495
Mitchell, J. L. et al. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. J. Clin. Investig. 130, 2845–2858 (2020).
pubmed: 32017709
pmcid: 7260031
doi: 10.1172/JCI130597
Williams, J. P. et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 3, e03821 (2014).
pubmed: 25217531
pmcid: 4199415
doi: 10.7554/eLife.03821
Giron, L. B. et al. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nat. Commun. 12, 3922 (2021).
pubmed: 34188039
pmcid: 8241829
doi: 10.1038/s41467-021-24077-w
Wedrychowski, A. et al. Transcriptomic signatures of human immunodeficiency virus post-treatment control. J. Virol. 97, e01254–01222 (2022).
pubmed: 36541802
pmcid: 9888280
Kök, A. et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol. 8, 127–140 (2015).
pubmed: 24985081
doi: 10.1038/mi.2014.50
Laanani, M. et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 pge 28ted HIV-DNA. Clin. Infect. Dis. 60, 1715–1721 (2015).
pubmed: 25737374
doi: 10.1093/cid/civ171
Schuetz, A. et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 10, e1004543 (2014).
pubmed: 25503054
pmcid: 4263756
doi: 10.1371/journal.ppat.1004543
Takata, H. et al. Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells. eBioMedicine 84, 104253 (2022).
pubmed: 36088683
pmcid: 9471490
doi: 10.1016/j.ebiom.2022.104253
Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014).
pubmed: 25042999
pmcid: 4126858
doi: 10.1038/nature13594
Colby, D. J. et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 24, 923–926 (2018).
pubmed: 29892063
pmcid: 6092240
doi: 10.1038/s41591-018-0026-6
Etemad, B., Esmaeilzadeh, E. & Li, J. Z. LearninG from the exceptions: HIV remission in post-treatment controllers. Front. Immunol. 10, 1749 (2019).
Antony, J. M. & MacDonald, K. S. A critical analysis of the cynomolgus macaque, Macaca fascicularis, as a model to test HIV-1/SIV vaccine efficacy. Vaccine 33, 3073–3083 (2015).
pubmed: 25510387
doi: 10.1016/j.vaccine.2014.12.004
Benlhassan-Chahour, K. et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J. Virol. 77, 12479–12493 (2003).
pubmed: 14610172
pmcid: 262554
doi: 10.1128/JVI.77.23.12479-12493.2003
Fray, E. J. et al. Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants. Cell Host Microbe. 0, https://doi.org/10.1016/j.chom.2023.01.016 (2023).
Mannioui, A. et al. Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. Retrovirology 6, 106 (2009).
pubmed: 19930655
pmcid: 2789052
doi: 10.1186/1742-4690-6-106
Policicchio, B. B., Pandrea, I. & Apetrei, C. Animal models for HIV cure research. Front. Immunol. 7, 12 (2016).
pubmed: 26858716
pmcid: 4729870
doi: 10.3389/fimmu.2016.00012
Harper, J. et al. IL-21 and IFNalpha therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques. Nat. Commun. 12, 2866 (2021).
pubmed: 34001890
pmcid: 8129202
doi: 10.1038/s41467-021-23189-7
Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430–1440 (2018).
pubmed: 30082858
pmcid: 6389357
doi: 10.1038/s41591-018-0130-7
Passaes, C. et al. Optimal maturation of the SIV-specific CD8+ T cell response after primary infection is associated with natural control of SIV: ANRS SIC study. Cell Rep. 32, 108174 (2020).
pubmed: 32966788
doi: 10.1016/j.celrep.2020.108174
Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).
pubmed: 28289286
pmcid: 5458531
doi: 10.1038/nature21435
Strongin, Z. et al. Virologic and immunologic features of simian immunodeficiency virus control post-ART interruption in rhesus macaques. J Virol. 94, e00338–00320 (2020).
pubmed: 32350073
pmcid: 7343203
doi: 10.1128/JVI.00338-20
Sáez-Cirión, A., Shin, S. Y., Versmisse, P., Barré-Sinoussi, F. & Pancino, G. Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat. Protoc. 5, 1033–1041 (2010).
pubmed: 20539279
doi: 10.1038/nprot.2010.73
Angin, M. et al. Preservation of lymphopoietic potential and virus suppressive capacity by CD8+ T cells in HIV-2–infected controllers. J. Immunol. 197, 2787–2795 (2016).
pubmed: 27566819
doi: 10.4049/jimmunol.1600693
Saez-Cirion, A. et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104, 6776–6781 (2007).
pubmed: 17428922
pmcid: 1851664
doi: 10.1073/pnas.0611244104
Tansiri, Y., Rowland-Jones, S. L., Ananworanich, J. & Hansasuta, P. Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated hiv suppression. PLoS ONE 10, e0118871 (2015).
pubmed: 25764310
pmcid: 4357381
doi: 10.1371/journal.pone.0118871
Lécuroux, C. et al. CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS ONE 8, e59767 (2013).
pubmed: 23555774
pmcid: 3612088
doi: 10.1371/journal.pone.0059767
Ndhlovu, Z. M. et al. Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity 43, 591–604 (2015).
pubmed: 26362266
pmcid: 4575777
doi: 10.1016/j.immuni.2015.08.012
Takata, H. et al. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. Sci. Transl. Med. 9, eaag1809 (2017).
pubmed: 28202771
pmcid: 5678930
doi: 10.1126/scitranslmed.aag1809
Perdomo-Celis, F. et al. Reprogramming dysfunctional CD8
Angin, M. et al. Metabolic plasticity of HIV-specific CD8(+) T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. Nat. Metab. 1, 704–716 (2019).
pubmed: 32694646
doi: 10.1038/s42255-019-0081-4
Hocqueloux, L. et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J. Antimicrob. Chemother. 68, 1169–1178 (2013).
pubmed: 23335199
doi: 10.1093/jac/dks533
Goulder, P. & Deeks, S. G. HIV control: is getting there the same as staying there? PLoS Pathog 14, e1007222 (2018).
pubmed: 30383857
pmcid: 6211749
doi: 10.1371/journal.ppat.1007222
Cheret, A. et al. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. J Antimicrob Chemother 70, 2108–2120 (2015).
pubmed: 25900157
doi: 10.1093/jac/dkv084
Molinos-Albert, L. M. et al. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Nat. Commun. 13, 1944 (2022).
pubmed: 35410989
pmcid: 9001681
doi: 10.1038/s41467-022-29511-1
Esmaeilzadeh, E. et al. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption. Sci. Transl. Med. 15, eabq4490 (2023).
pubmed: 37163616
pmcid: 10576978
doi: 10.1126/scitranslmed.abq4490
Molinos-Albert, L. M. et al. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller. Cell Host Microbe. 31, 1275–1287.e1278 (2023).
pubmed: 37433296
doi: 10.1016/j.chom.2023.06.006
Appay, V. et al. Dynamics of T cell responses in HIV infection. J. Immunol. 168, 3660–3666 (2002).
pubmed: 11907132
doi: 10.4049/jimmunol.168.7.3660
Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106–111 (2001).
pubmed: 11242051
doi: 10.1038/35065118
Dalod, M. et al. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Invest. 104, 1431–1439 (1999).
pubmed: 10562305
pmcid: 409838
doi: 10.1172/JCI7162
Cabral-Piccin, M. P. et al. Primary role of type I interferons for the induction of functionally optimal antigen-specific CD8(+) T cells in HIV infection. EBioMedicine 91, 104557 (2023).
pubmed: 37058769
pmcid: 10130611
doi: 10.1016/j.ebiom.2023.104557
Lahaye, X. et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity 39, 1132–1142 (2013).
pubmed: 24269171
doi: 10.1016/j.immuni.2013.11.002
Manel, N. et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467, 214–217 (2010).
pubmed: 20829794
pmcid: 3051279
doi: 10.1038/nature09337
Almeida, J. R. et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351–6360 (2009).
pubmed: 19389882
pmcid: 2710928
doi: 10.1182/blood-2009-02-206557
Migueles, S. A. et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009–1021 (2008).
pubmed: 19062316
pmcid: 2622434
doi: 10.1016/j.immuni.2008.10.010
Shasha, D. et al. Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors. J. Leukoc Biol. 100, 1425–1433 (2016).
pubmed: 27406996
pmcid: 5109996
doi: 10.1189/jlb.4A0915-422R
Rutishauser, R. L. et al. TCF-1 regulates HIV-specific CD8
Sekine, T. et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci. Immunol. 5, https://doi.org/10.1126/sciimmunol.aba7918 (2020).
Blazkova, J. et al. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat. Med. 27, 1893–1898 (2021).
pubmed: 34711975
doi: 10.1038/s41591-021-01503-6
Essat, A. et al. A Genetic fingerprint associated with durable HIV remission after interruption of antiretroviral treatment. Anrs Visconti. Preprint available at SSRN. https://doi.org/10.2139/ssrn.4540849 (2023).
Horowitz, A. et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci. Immunol. 1, eaag1672–eaag1672 (2016).
pubmed: 27868107
pmcid: 5110269
doi: 10.1126/sciimmunol.aag1672
Neildez, O. et al. Selective quasispecies transmission after systemic or mucosal exposure of macaques to simian immunodeficiency virus. Virology 243, 12–20 (1998).
pubmed: 9527911
doi: 10.1006/viro.1997.9026
Damouche, A. et al. Adipose Tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog. 11, e1005153 (2015).
pubmed: 26402858
pmcid: 4581628
doi: 10.1371/journal.ppat.1005153
Aarnink, A. et al. Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque. Immunogenetics 63, 267–274 (2011).
pubmed: 21234560
doi: 10.1007/s00251-010-0504-6
Mee, E. T. et al. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics 61, 327–339 (2009).
pubmed: 19337730
doi: 10.1007/s00251-009-0369-8
Hofmann-Lehmann, R. et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses. 16, 1247–1257 (2000).
pubmed: 10957722
doi: 10.1089/08892220050117014
Daniel, M. D. et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228, 1201–1204 (1985).
pubmed: 3159089
doi: 10.1126/science.3159089
Rascle, P. et al. NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections. Commun. Biol. 5, 1–11 (2022).
doi: 10.1038/s42003-022-03619-y
O’Doherty, U., Swiggard, W. J. & Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10074–10080 (2000).
pubmed: 11024136
pmcid: 102046
doi: 10.1128/JVI.74.21.10074-10080.2000